DE69840998D1 - Ricin-ähnliche toxine zur therapie von kreb, viraler oder parasitärer infektionen - Google Patents

Ricin-ähnliche toxine zur therapie von kreb, viraler oder parasitärer infektionen

Info

Publication number
DE69840998D1
DE69840998D1 DE69840998T DE69840998T DE69840998D1 DE 69840998 D1 DE69840998 D1 DE 69840998D1 DE 69840998 T DE69840998 T DE 69840998T DE 69840998 T DE69840998 T DE 69840998T DE 69840998 D1 DE69840998 D1 DE 69840998D1
Authority
DE
Germany
Prior art keywords
ricin
cancer
viral
nucleic acid
infection
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69840998T
Other languages
German (de)
English (en)
Inventor
Thor Borgford
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Twinstrand Holdings Inc Winnipeg Manitoba Ca
Original Assignee
Twinstrand Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Twinstrand Therapeutics Inc filed Critical Twinstrand Therapeutics Inc
Application granted granted Critical
Publication of DE69840998D1 publication Critical patent/DE69840998D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/415—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from plants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Botany (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)
DE69840998T 1997-04-30 1998-04-30 Ricin-ähnliche toxine zur therapie von kreb, viraler oder parasitärer infektionen Expired - Lifetime DE69840998D1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US4514897P 1997-04-30 1997-04-30
US6371597P 1997-10-29 1997-10-29
PCT/CA1998/000394 WO1998049311A2 (en) 1997-04-30 1998-04-30 Ricin-like toxin variants for treatment of cancer, viral or parasitic infections

Publications (1)

Publication Number Publication Date
DE69840998D1 true DE69840998D1 (de) 2009-09-03

Family

ID=26722431

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69840998T Expired - Lifetime DE69840998D1 (de) 1997-04-30 1998-04-30 Ricin-ähnliche toxine zur therapie von kreb, viraler oder parasitärer infektionen

Country Status (8)

Country Link
US (3) US6593132B1 (cg-RX-API-DMAC7.html)
EP (1) EP0977862B8 (cg-RX-API-DMAC7.html)
JP (1) JP4566290B2 (cg-RX-API-DMAC7.html)
AT (1) ATE437229T1 (cg-RX-API-DMAC7.html)
AU (1) AU7023798A (cg-RX-API-DMAC7.html)
CA (1) CA2288943C (cg-RX-API-DMAC7.html)
DE (1) DE69840998D1 (cg-RX-API-DMAC7.html)
WO (1) WO1998049311A2 (cg-RX-API-DMAC7.html)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6361946B1 (en) 1997-02-05 2002-03-26 Licentia Ltd Vascular endothelial growth factor C (VEGF-C) protein and gene, mutants thereof, and uses thereof
US7247715B2 (en) * 1997-04-30 2007-07-24 Twinstrand Therapeutics Inc. Ricin-like toxin variants for treatment of cancer, viral or parasitic infections
AU7636800A (en) 1999-10-04 2001-05-10 Twinstrand Therapeutics Inc. Improved ricin-like toxins for treatment of cancer
GB0100551D0 (en) * 2001-01-09 2001-02-21 Queen Mary & Westfield College Protein
EP1483298A4 (en) 2002-02-11 2007-03-14 Zymogenetics Inc MATERIALS AND METHODS FOR PREPARING DIMERED GROWTH FACTORS
AU2004257206A1 (en) * 2003-07-10 2005-01-27 Wyeth Holdings Corporation Recombinant expression of Streptococcus pyogenes cysteine protease and immunogenic compositions thereof
EP1730282A4 (en) * 2004-03-24 2007-05-09 Twinstrand Therapeutics Inc GLYCOSYLATION VARIANTS OF RICINE-LIKE PROTEINS
ATE467641T1 (de) * 2004-03-26 2010-05-15 Molecular Templates Inc Bibliothek von toxin mutanten und deren verwendung
US20060024722A1 (en) * 2004-07-30 2006-02-02 Mark Fischer-Colbrie Samples for detection of oncofetal fibronectin and uses thereof
DE102005002978B4 (de) * 2005-01-21 2013-04-25 Merz Pharma Gmbh & Co. Kgaa Rekombinante Expression von Proteinen in einer disulfidverbrückten, zweikettigen Form
CA2664549A1 (en) 2005-09-26 2007-03-29 University Health Network Library from toxin mutants, and methods of using same
DE602006012358D1 (de) * 2005-11-18 2010-04-01 Dabur Pharma Ltd Zielgerichtete fusionsproteine für die krebstherapie
WO2008157263A2 (en) * 2007-06-15 2008-12-24 Arkansas State University Methods of delivery of molecules to cells using a ricin subunit and compositions relating to same
EP2379720B1 (en) 2009-01-20 2016-08-17 Alona Zilberberg Mir-21 promoter driven targeted cancer therapy
US9321847B2 (en) * 2010-09-20 2016-04-26 Ramot At Tel Aviv University Ltd. Activatable toxin complexes comprising a cleavable inhibitory peptide
US10513539B2 (en) 2011-02-10 2019-12-24 Ruprecht-Karls-Universitat Heidelberg Hydrophobic modified peptides and their use for liver specific targeting
CN103402546B (zh) 2011-02-10 2018-04-13 海德堡鲁普雷希特卡尔斯大学 用于肝特异性诊断的疏水性修饰肽
WO2012123755A1 (en) 2011-03-17 2012-09-20 The University Of Birmingham Re-directed immunotherapy
JP7134461B2 (ja) * 2018-03-23 2022-09-12 国立大学法人金沢大学 マラリア治療剤、マラリア予防剤及び抗マラリア自然免疫賦活剤
KR102698801B1 (ko) 2020-12-30 2024-08-29 호크아이 바이오 리미티드 바이오마커 검출을 위한 순수 그래핀 기반 바이오센서 및 관련 코어 입자, 재료 구성 방법 및 시스템
TW202328170A (zh) * 2021-09-14 2023-07-16 美商艾希利歐發展股份有限公司 可裂解連接子
WO2025151752A1 (en) 2024-01-10 2025-07-17 Xilio Development, Inc. Masked il-2 cytokines and methods of use thereof

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2442A (en) 1842-02-01 Floating dry-dock
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
EP0145111B1 (en) * 1983-07-15 1990-05-09 The University Of Warwick Dna sequence coding for a plant toxin of the ricin type, or a portion thereof
US4736866B1 (en) 1984-06-22 1988-04-12 Transgenic non-human mammals
JPS6147500A (ja) 1984-08-15 1986-03-07 Res Dev Corp Of Japan キメラモノクロ−ナル抗体及びその製造法
EP0173494A3 (en) 1984-08-27 1987-11-25 The Board Of Trustees Of The Leland Stanford Junior University Chimeric receptors by dna splicing and expression
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US4869903A (en) 1987-05-29 1989-09-26 Genelabs Incorporated Method of selectively inhibiting HIV
WO1990010457A1 (en) 1989-03-14 1990-09-20 New York University Method of treating hiv infections using immunotoxins
US5128460A (en) 1989-04-04 1992-07-07 Genelabs Incorporated Recombinant trichosanthin and coding sequence
US5101025A (en) 1989-04-04 1992-03-31 Genelabs Incorporated Recombinant trichosanthin and coding sequence
US5248606A (en) * 1990-06-11 1993-09-28 Dowelanco Dna encoding inactive precursor and active forms of maize ribosome inactivating protein
GB9021679D0 (en) 1990-10-05 1990-11-21 Gorman Scott David Antibody preparation
US5677274A (en) * 1993-02-12 1997-10-14 The Government Of The United States As Represented By The Secretary Of The Department Of Health And Human Services Anthrax toxin fusion proteins and related methods
EP0909322B1 (en) * 1996-04-30 2005-11-16 Twinstrand Therapeutics Inc. Antiviral ricin-like proteins

Also Published As

Publication number Publication date
ATE437229T1 (de) 2009-08-15
EP0977862A2 (en) 2000-02-09
JP2001523961A (ja) 2001-11-27
JP4566290B2 (ja) 2010-10-20
US7375186B2 (en) 2008-05-20
US20110144004A1 (en) 2011-06-16
AU7023798A (en) 1998-11-24
CA2288943C (en) 2011-02-01
EP0977862B1 (en) 2009-07-22
CA2288943A1 (en) 1998-11-05
WO1998049311A3 (en) 1999-02-11
WO1998049311A2 (en) 1998-11-05
US6593132B1 (en) 2003-07-15
EP0977862B8 (en) 2009-09-16
US20040009551A1 (en) 2004-01-15

Similar Documents

Publication Publication Date Title
ATE437229T1 (de) Ricin-ähnliche toxine zur therapie von kreb, viraler oder parasitärer infektionen
Utkin Animal venom studies: Current benefits and future developments
RU95115239A (ru) Аналог эритропоэтина
BR7908410A (pt) Meio para deteccao de anticorpos de vhb no soro do sangue,e processo para deteccao da presenca da infeccao por virus da hepatite b em seres humanos
DE69934967D1 (de) Verfahren zur verminderung der immunogenität von proteinen
NO20013701D0 (no) HER-2/neu-fusjonsproteiner
CY1107628T1 (el) Ανθρωπινα ctla-4 αντισωματα και χρησεις αυτων
DE69032484D1 (de) Zusammensetzungen und deren verwendung zur förderung der immunopotentiation
CY1106926T1 (el) Γονιδιο που κωδικοποιει την ηλιομυκινη και η χρηση της
SE8703225L (sv) Monoklonala antikroppar och peptider anvendbara vid behandling och diagnostisering av hiv-infektioner
BR112022022503A2 (pt) Anticorpos neutralizantes que se ligam à proteína s de sars-cov-2
ATE165980T1 (de) Nukleinsaürefragmente, die mannose bindende fragmente vom menschlichen mannosebindenden protein kodieren
BR0012919A (pt) Vacina para uso na profilaxia e/ou no tratamento da sìndrome de ponto branco (white spot syndrome) em crustáceos, proteìna estrutural derivada do vìrus da sìndrome de ponto branco, sequência de ácido nucléico, uso de uma proteìna estrutural, composição farmacêutica, anticorpos, vacina ou formulação farmacêutica, e, kit diagnóstico para detecção de wssv
Korir et al. Proteomic studies of Plasmodium knowlesi SICA variant antigens demonstrate their relationship with P. falciparum EMP1
DK0750672T3 (da) DNA-sekvenser for matrix-metalproteaser, deres tilvejebringelse og anvendelse
DE69129034D1 (de) Molekulare klone von hiv-1 und deren verwendung
RU94045907A (ru) Вич-антитела человека или их фрагменты, экспрессионные кассеты, клетки-хозяева, фармацевтические композиции, способ защиты
TR200400049T2 (tr) Eimeria maxima gametositinden rekombinant 56 ve 82 kda antijenleri kodlayan nükleik asitler
EA200100700A1 (ru) Гены и белки и их применение
UY26763A1 (es) Inmunización del ganado lacteo con proteína gapc quimérica contra infección por estreptococo.
WO2001025267A3 (en) Improved ricin-like toxins for treatment of cancer
CA2252799A1 (en) Antiviral ricin-like proteins
CY1105947T1 (el) Νουκλεϊνικα οξεα και πρωτεϊνες του γονιδιου mhp3 του mycoplasma hyopneumoniae και χρησεις αυτων
DE60035485D1 (de) IDENTIFIZIERUNG VON SPEZIFISCHEN DIFFERENZIELL EXPRIMIERTEN ANTIGENEN AUS MYCOBACTERIUM UND MEDIZINISCHE VERWENDUNG DER MYCOBAKTERIUMPROTEINE Rv0068 UND Rv3407
NO945031D0 (no) Anvendelse av en hymenopteragift til fremstilling av et medikament for behandling av DNA-virusinfeksjoner

Legal Events

Date Code Title Description
8327 Change in the person/name/address of the patent owner

Owner name: TWINSTRAND HOLDINGS INC., WINNIPEG, MANITOBA, CA

8364 No opposition during term of opposition